Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Front Public Health ; 9: 682112, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34123996

RESUMO

An interdisciplinary group from two higher-education institutions in Philadelphia developed a novel framework for interprofessional education. This framework was applied to two different scenarios disease outbreak and natural disaster, which were used in simulations in 2018 and 2020. By design, these simulations included students from a broad range of disciplines, beyond the typical healthcare fields. Students were first grouped by discipline and were then placed in interdisciplinary teams for the rest of the scenario. Students were administered four surveys throughout which included 10 point-Likert scale and free response items. A statistically significant post-simulation increase in student interest and confidence was found. Survey analysis also revealed higher scores of positive group behaviors among interdisciplinary teams when compared to discipline groups. Importantly, students realized the importance of broad representation of disciplines for disaster preparedness. The PennDemic framework may be helpful for teams looking to develop simulations to build interest and confidence in disaster preparedness/response and interdisciplinary teamwork.


Assuntos
Desastres , Ocupações em Saúde , Humanos , Estudos Interdisciplinares , Philadelphia , Estudantes
2.
Trop Med Infect Dis ; 4(2)2019 Apr 10.
Artigo em Inglês | MEDLINE | ID: mdl-30974815

RESUMO

The global burden of infectious diseases and the increased attention to natural, accidental, and deliberate biological threats has resulted in significant investment in infectious disease research. Translating the results of these studies to inform prevention, detection, and response efforts often can be challenging, especially if prior relationships and communications have not been established with decision-makers. Whatever scientific information is shared with decision-makers before, during, and after public health emergencies is highly dependent on the individuals or organizations who are communicating with policy-makers. This article briefly describes the landscape of stakeholders involved in information-sharing before and during emergencies. We identify critical gaps in translation of scientific expertise and results, and biosafety and biosecurity measures to public health policy and practice with a focus on One Health and zoonotic diseases. Finally, we conclude by exploring ways of improving communication and funding, both of which help to address the identified gaps. By leveraging existing scientific information (from both the natural and social sciences) in the public health decision-making process, large-scale outbreaks may be averted even in low-income countries.

3.
Pediatr Diabetes ; 19(4): 761-768, 2018 06.
Artigo em Inglês | MEDLINE | ID: mdl-29243325

RESUMO

BACKGROUND: Managing type 1 diabetes mellitus (T1DM) in preschool-aged children has unique challenges that can negatively impact glycemic control and parental coping. OBJECTIVE: To evaluate the impact of a camp-based multi-component intervention on glycated hemoglobin A1c (HbA1c) in young children with T1DM and psychosocial measures for their parents. SUBJECTS AND METHODS: Two separate cohorts of 18 children (ages 3-5 years) and their families participated in a camp-based intervention that included didactic and interactive parent education, child-centered education and family-based recreational activities. In Camp 1.0, measures of HbA1c, parental fear of hypoglycemia, mealtime behaviors and quality of life (QOL) were compared before and after an initial session (I) and follow-up booster session (II) 6 months later. Based on these results, the intervention was consolidated into 1 session (Camp 2.0) and repeated with additional measures of parental stress and parental self-efficacy with diabetes management tasks. RESULTS: Participants in Camp 2.0 exhibited a significant decrease in mean HbA1c level (-0.5%, P = .002) before and after camp. Mothers exhibited a significant improvement in diabetes-specific QOL (Camp 1.0/Session I and Camp 2.0) and reduction in stress as measured on the Pediatric Inventory for Parent (PIP) assessment (Camp 2.0). The booster session in Camp 1.0 showed no added benefit. CONCLUSIONS: A family centered, camp-based multi-component intervention in young children with T1DM improved HbA1c and perceived QOL and stress in their mothers.


Assuntos
Diabetes Mellitus Tipo 1/terapia , Educação em Saúde/métodos , Pais/educação , Idade de Início , Cuidadores/educação , Cuidadores/psicologia , Criança , Pré-Escolar , Diabetes Mellitus Tipo 1/epidemiologia , Diabetes Mellitus Tipo 1/psicologia , Família/psicologia , Estudos de Viabilidade , Feminino , Educação em Saúde/organização & administração , Humanos , Atividades de Lazer , Masculino , Relações Pais-Filho , Pais/psicologia , Projetos Piloto
4.
Clin J Oncol Nurs ; 15 Suppl: 41-52, 2011 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-21816709

RESUMO

As in many other cancers, survivorship of multiple myeloma involves handling treatment, recovery from therapeutic interventions, the effects of the disease, and ongoing therapies. Although mobility challenges vary among survivors of multiple myeloma, these patients have an increased risk of impaired mobility because of side effects of therapy and the pathology of the disease, as well as other factors (e.g., increasing age). Health maintenance increasingly is becoming a part of the cancer control continuum, and nurses have the opportunity to help survivors of multiple myeloma optimize their functional mobility and safety, thereby preserving quality of life. The purpose of these practice recommendations is to provide the healthcare professional with information on mobility, fall risk, and planned activity as an integral part of the plan of care for patients with multiple myeloma. Tools for nurses and physicians for assessing and evaluating the newly diagnosed patient, the patient undergoing treatment, and the long-term survivor of multiple myeloma will be provided.


Assuntos
Liderança , Movimento , Mieloma Múltiplo/fisiopatologia , Segurança , Sobreviventes , Enfermagem Baseada em Evidências , Exercício Físico , Humanos , Mieloma Múltiplo/enfermagem , Qualidade de Vida , Sociedades de Enfermagem
5.
Blood ; 112(8): 3122-5, 2008 Oct 15.
Artigo em Inglês | MEDLINE | ID: mdl-18669874

RESUMO

Smoldering multiple myeloma (SMM) is usually followed expectantly without therapy. We conducted a phase 2 trial in 76 eligible patients with SMM, combining thalidomide (THAL, 200 mg/d) with monthly pamidronate. In the first 2 years, THAL dose reduction was required in 86% and drug was discontinued in 50%. Within 4 years, 63% improved, including 25% qualifying for partial response (PR); by then, 34 patients had progressed and 17 required salvage therapy. Unexpectedly, attaining PR status was associated with a shorter time to salvage therapy for disease progression (P < .001), perhaps reflecting greater drug sensitivity of more aggressive disease. Low beta-2-microglobulin levels less than 2 mg/L were independently associated with superior overall and event-free survival. Four-year survival and event-free survival estimates of 91% and 60%, respectively, together with a median postsalvage therapy survival of more than 5 years justify the conduct of a prospective randomized clinical trial to determine the clinical value of preemptive therapy in SMM. Trial registered at http://www.clinicaltrials.gov under identifier NCT00083382.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Medula Óssea/patologia , Difosfonatos/administração & dosagem , Imunossupressores/administração & dosagem , Mieloma Múltiplo/tratamento farmacológico , Mieloma Múltiplo/prevenção & controle , Lesões Pré-Cancerosas/tratamento farmacológico , Talidomida/administração & dosagem , Progressão da Doença , Intervalo Livre de Doença , Humanos , Análise Multivariada , Pamidronato , Terapia de Salvação , Fatores de Tempo , Resultado do Tratamento
6.
Blood ; 112(4): 1035-8, 2008 Aug 15.
Artigo em Inglês | MEDLINE | ID: mdl-18502827

RESUMO

The clinical outcomes of 169 patients enrolled in the first clinical trial of thalidomide for advanced or refractory myeloma are updated. Seventeen patients remain alive and 10 are event-free, with a median follow-up of 9.2 years. According to multivariate analysis of pretreatment variables, cytogenetic abnormalities, present in 47% of patients within 3 months of enrollment, and lambda light chain isotype both affected overall survival and event-free survival adversely. Forty percent of the 58 patients lacking these 2 unfavorable features, one-half of whom had no disease recurrence, survived at least 6 years, in contrast to fewer than 5% among those with 1 or 2 risk features (P < .001). Patients who had received cumulative thalidomide doses in excess of 42 g in the first 3 months enjoyed superior overall and event-free survival. The poor outcome associated with lambda-type myeloma may relate to its overrepresentation in molecularly defined high-risk disease gleaned from studies in newly diagnosed myeloma.


Assuntos
Mieloma Múltiplo/tratamento farmacológico , Talidomida/administração & dosagem , Aberrações Cromossômicas , Intervalo Livre de Doença , Seguimentos , Humanos , Cadeias lambda de Imunoglobulina , Mieloma Múltiplo/mortalidade , Prognóstico , Análise de Sobrevida , Taxa de Sobrevida , Talidomida/toxicidade , Resultado do Tratamento
7.
Clin J Oncol Nurs ; 12(3 Suppl): 9-12, 2008 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-18490252

RESUMO

Nurses play an essential role in managing the care of patients with multiple myeloma, who require education and support to receive and adhere to optimal therapy. The International Myeloma Foundation created a Nurse Leadership Board comprised of oncology nurses from leading cancer centers and community practices. An assessment survey identified the need for specific recommendations for managing key side effects of novel antimyeloma agents. Myelosuppression, thromboembolic events, peripheral neuropathy, steroid toxicities, and gastrointestinal side effects were selected for the first consensus statements. The board developed recommendations for healthcare providers in any medical setting, including grading of side-effect toxicity and strategies for managing the side effects in general, with specific recommendations pertaining to the novel agents.


Assuntos
Antineoplásicos/efeitos adversos , Consenso , Liderança , Mieloma Múltiplo/tratamento farmacológico , Sociedades de Enfermagem , Antineoplásicos/uso terapêutico , Humanos , Mieloma Múltiplo/enfermagem
8.
Clin J Oncol Nurs ; 12(3 Suppl): 37-52, 2008 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-18490256

RESUMO

The novel immunomodulatory drugs lenalidomide and thalidomide and the novel proteasome inhibitor bortezomib can cause gastrointestinal side effects, including constipation, diarrhea, nausea, and vomiting, which can have a deleterious effect on quality of life and interfere with optimal therapy. The International Myeloma Foundation's Nurse Leadership Board developed this consensus statement for the management of gastrointestinal side effects associated with novel therapies to be used by healthcare providers in any medical setting. It includes grading criteria and general recommendations for assessing and managing the side effects. Although constipation, diarrhea, nausea, and vomiting are expected side effects associated with novel therapies for multiple myeloma, they are manageable with appropriate medical interventions.


Assuntos
Antineoplásicos/efeitos adversos , Trato Gastrointestinal/efeitos dos fármacos , Liderança , Mieloma Múltiplo/tratamento farmacológico , Sociedades de Enfermagem , Trato Gastrointestinal/fisiopatologia , Humanos , Fatores de Risco
9.
Cancer ; 112(12): 2720-5, 2008 Jun 15.
Artigo em Inglês | MEDLINE | ID: mdl-18433012

RESUMO

BACKGROUND: Total Therapy (TT) programs are complex and their execution over the course of several years is fraught with patient attrition due to failure and toxicity of therapy and patient/physician acceptance. METHODS: The impact of completion versus noncompletion of intended treatment steps was examined in protocols TT2 (n=668) and TT3 (n=303) on overall survival (OS) and event-free survival (EFS). RESULTS: By using appropriate landmarks of 36 months with TT2 and 18 months with TT3, representing the maxima to completion of premaintenance phases, postconsolidation OS was superior for 211 patients completing versus 311 patients not completing premaintenance steps on TT2 (P=.001), which also pertained to the 161 patients completing versus 47 not completing intended treatment steps on TT3 (P=.01). On multivariate analysis that included all patients, completion of therapy independently favored longer OS and EFS in the context of both standard prognostic factors and gene expression profiling-defined risk; in addition, TT3 prolonged EFS over results obtained with TT2. CONCLUSIONS: 1) Completion of intended therapy was a significant independent variable conferring superior OS and EFS in TT programs; and 2) after adjusting for completion of therapy, EFS was still superior with TT3 versus TT2, supporting the beneficial role of bortezomib included in TT3. Collectively, these data point to the importance of designing clinical trials that balance the treatment requirements for disease control with host acceptance and tolerance.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Esquema de Medicação , Mieloma Múltiplo/tratamento farmacológico , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Ensaios Clínicos como Assunto , Terapia Combinada , Intervalo Livre de Doença , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Indução de Remissão , Projetos de Pesquisa , Taxa de Sobrevida
10.
Br J Haematol ; 138(2): 176-85, 2007 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-17593024

RESUMO

Total therapy 3 incorporated bortezomib into a melphalan-based tandem transplant regimen for 303 newly diagnosed patients with myeloma. Induction chemotherapy prior to and consolidation chemotherapy after transplants each consisted of two cycles of VTD-PACE (bortezomib, thalidomide, dexamethasone and 4-d continuous infusions of cis-platin, doxorubicin, cyclophosphamide, etoposide); 3-year maintenance comprised monthly cycles of VTD in the first and TD in the remaining years. The median age was 59 years (age >64 years, 28%). A minimum of 20 x 10(6) CD34 cells/kg was collected in 87% of patients; 83% completed both transplants, and only 5% suffered a treatment-related death. At 24 months, 83% had achieved near-complete remission, which was sustained in 88% at 2 years from its onset. With a median follow-up of 20 months, 2-year estimates of event-free and overall survival were 84% and 86% respectively. The 44 patients who experienced an event more often had a high-risk gene array profile, cytogenetic abnormalities and indicators of high lactate dehydrogenase, beta-2-microglobulin, creatinine and International Staging System stage. Toxicities of grade > 2 included thrombo-embolic events in 27% and peripheral neuropathy in 12%. Results of this phase-2 study demonstrated that bortezomib could be safely combined with multi-agent chemotherapy, effecting near-complete remission status and 2-year survival rates in more than 80% of patients.


Assuntos
Antineoplásicos/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Ácidos Borônicos/administração & dosagem , Mieloma Múltiplo/tratamento farmacológico , Pirazinas/administração & dosagem , Idoso , Inibidores da Angiogênese/administração & dosagem , Antineoplásicos/efeitos adversos , Antineoplásicos Alquilantes/administração & dosagem , Antineoplásicos Hormonais/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Ácidos Borônicos/efeitos adversos , Bortezomib , Terapia Combinada/métodos , Dexametasona/administração & dosagem , Feminino , Humanos , Estimativa de Kaplan-Meier , Masculino , Melfalan/administração & dosagem , Pessoa de Meia-Idade , Mieloma Múltiplo/mortalidade , Mieloma Múltiplo/cirurgia , Pirazinas/efeitos adversos , Transplante de Células-Tronco/métodos , Talidomida/administração & dosagem , Resultado do Tratamento
11.
Br J Haematol ; 135(2): 158-64, 2006 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-16939489

RESUMO

Total Therapy 1, the first tandem autotransplant trial for newly diagnosed patients with multiple myeloma, was designed to increase the frequency of complete response (CR) and thereby extend survival. With a median follow-up of 12 years, 62 of 231 initially enrolled patients are alive (17% at 15 years); 31 remain event free (7% at 15 years) including 16 of 94 (41%) that initially achieved CR. Currently alive patients less frequently had cytogenetic abnormalities (CAs) at baseline (P = 0.002), postenrolment (P < 0.001) and at relapse (P = 0.004); elevations of serum C-reactive protein (CRP) (P = 0.003) and lactate dehydrogenase (P = 0.029), anaemia (P = 0.029) and they more often completed two transplants within 12 months (P = 0.019). Postenrolment overall survival (OS) and event-free survival (EFS) were superior in the absence of CA of the hypodiploidy or deletion 13 variety (P < 0.001 and 0.037 respectively) and in the presence of low CRP at baseline (P = 0.001 and 0.017 respectively). Postrelapse survival was longer in the absence of CA at relapse (P < 0.001), IgA isotype (P = 0.002), International Staging System stage 3 (P = 0.014), and when patients had two protocol transplants prior to relapse (P = 0.038). Ten-year EFS and OS could be accomplished in 15% and 33% of patients, respectively, when all agents available in 1989, especially high-dose melphalan, were applied together upfront for the management of myeloma.


Assuntos
Transplante de Células-Tronco Hematopoéticas/métodos , Mieloma Múltiplo/terapia , Idoso , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Progressão da Doença , Esquema de Medicação , Métodos Epidemiológicos , Feminino , Humanos , Masculino , Melfalan/administração & dosagem , Pessoa de Meia-Idade , Mieloma Múltiplo/tratamento farmacológico , Prognóstico , Recidiva , Resultado do Tratamento
12.
Artigo em Inglês | MEDLINE | ID: mdl-27818571

RESUMO

Chromosome breakage analysis with Mitomycin C (MMC) and sister chromatid exchanges (SCE) were obtained on 10 computer operators with computer exposure for a minimum of 3 hours per day for 4 years and 10 control subjects matched for age and personal lifestyle. No difference was found between the two groups in the total number of chromatid and chromosome aberrations in cells grown at 48 and/or 96 hours in Mitomycin C (20 or 50 ng/ml-final concentration). The average number of SCE per cell in approximately 30 cells from each person was 6.4 ± 1.1 (mean ± standard deviation) for the computer operators and 9.2 ± 1.6 for the controls. This difference was significant (p <.001). The replicative index was significantly higher (p<.01) in computer operators than in control subjects. The number of SCE appeared not to be influenced by the years of computer exposure. Additional studies with larger sample sizes will be needed to identify if significant differences exist in cell kinetics and sister chromatid exchanges in individuals employed as computer operators.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...